Heidelberg University

NovoNutrients Hires Four Technology Leaders to Make Protein From CO2

Retrieved on: 
Tuesday, January 4, 2022
Heidelberg University, CTO, Chemical engineering, Safety, University, Biology, Doctor of Philosophy, Kedar, UC, Indian Institute of Technology (BHU) Varanasi, DNA, Molecular biology, Food, Institute, Institute of Chemical Technology, Hydrogen, Microbiology, Publication, Bhupendra, Siluria Technologies, Health, MBA, Greenhouse, Bacteria, Yeast, DuPont Central Research, University of California, Berkeley, Codexis, Technical, Biochemical engineering, DeVry University, BS, VP, Stanford University, Carbon, CO2, Fine chemical, Management, Calysta, Technology, Amyris, Engineering, Fermentation, Research, Satish

NovoNutrients' CEO, David Tze, said, "we are now fully positioned to build on our technology foundation and become a leading protein ingredients company, with the addition of these four industry experts.

Key Points: 
  • NovoNutrients' CEO, David Tze, said, "we are now fully positioned to build on our technology foundation and become a leading protein ingredients company, with the addition of these four industry experts.
  • Satish Lakhapatri, VP Engineering, joins NovoNutrients after nearly four years with industrial biotech company Calysta, where he was the Director of Engineering.
  • About NovoNutrients https://www.novonutrients.com NovoNutrients is the food and feed from CO2 bio company that cleanly transforms carbon dioxide emissions into microbial alternative protein ingredients.
  • Also using other byproduct streams and hydrogen, this low-cost, highly-scalable technology addresses the growing demand of rising global standards of living.

European Wellness Join Forces with Heidelberg University Germany in Safety and Toxicity Tests for Preclinical Anti-Aging Peptides Studies

Retrieved on: 
Wednesday, November 17, 2021
List of Nobel laureates, University, Commercial, European Society for Engineering Education, Cosmeceutical, FOC, Hospital, Knowledge, Peptide, Medicine, Safety, Exosome, Cell biology, NOP, Regenerative medicine, Research, EWA, B cell, Toxicity, PSC, University of Rochester Medical Center, Therapy, Richardson Recreation and Wellness Centre, Investigational New Drug, Group, Heidelberg University, The Wells Academy, IND, Medical device, Fine chemical, Pharmaceutical industry

HEIDELBERG, Germany, Nov. 17, 2021 /PRNewswire/ -- European Wellness Academy (EWA), a member of European Wellness Biomedical Group (EWBG), recently signed its second research contract involving General In Vitro/In Vivo Safety and Toxicity Tests for Preclinical Studies of Regenerative Peptides with Heidelberg University.

Key Points: 
  • HEIDELBERG, Germany, Nov. 17, 2021 /PRNewswire/ -- European Wellness Academy (EWA), a member of European Wellness Biomedical Group (EWBG), recently signed its second research contract involving General In Vitro/In Vivo Safety and Toxicity Tests for Preclinical Studies of Regenerative Peptides with Heidelberg University.
  • The research mandate serves to obtain further scientific knowledge on the preclinical safety and toxicity of regenerative peptides.
  • The research partner, Heidelberg University is Germany's oldest university and one of the strongest research universities in all of Europe.
  • Fifty-six Nobel Laureates share a connection with Heidelberg University or the city of Heidelberg, ten of whom have taught there as professors.

European Wellness Join Forces with Heidelberg University Germany in Safety and Toxicity Tests for Preclinical Anti-Aging Peptides Studies

Retrieved on: 
Wednesday, November 17, 2021
List of Nobel laureates, University, Commercial, European Society for Engineering Education, Cosmeceutical, FOC, Hospital, Knowledge, Peptide, Medicine, Safety, Exosome, Cell biology, NOP, Regenerative medicine, Research, EWA, B cell, Toxicity, PSC, University of Rochester Medical Center, Therapy, Richardson Recreation and Wellness Centre, Investigational New Drug, Group, Heidelberg University, The Wells Academy, IND, Medical device, Fine chemical, Pharmaceutical industry

HEIDELBERG, Germany, Nov. 17, 2021 /PRNewswire/ -- European Wellness Academy (EWA), a member of European Wellness Biomedical Group (EWBG), recently signed its second research contract involving General In Vitro/In Vivo Safety and Toxicity Tests for Preclinical Studies of Regenerative Peptides with Heidelberg University.

Key Points: 
  • HEIDELBERG, Germany, Nov. 17, 2021 /PRNewswire/ -- European Wellness Academy (EWA), a member of European Wellness Biomedical Group (EWBG), recently signed its second research contract involving General In Vitro/In Vivo Safety and Toxicity Tests for Preclinical Studies of Regenerative Peptides with Heidelberg University.
  • The research mandate serves to obtain further scientific knowledge on the preclinical safety and toxicity of regenerative peptides.
  • The research partner, Heidelberg University is Germany's oldest university and one of the strongest research universities in all of Europe.
  • Fifty-six Nobel Laureates share a connection with Heidelberg University or the city of Heidelberg, ten of whom have taught there as professors.

European Wellness Collaborates with Heidelberg University Germany to Conduct Efficacy Studies of Peptides and Cell Therapy Research

Retrieved on: 
Wednesday, October 27, 2021
Safety, Lung, EWG, Muscular dystrophy, Peptide, Sleep, Research, Microsoft, Academy, Group, Exosome, Heidelberg University, FOC, Regeneration, Degenerative disease, Eye, Kidney, Medicine, Rejuvenation, B cell, Ageing, Cellular senescence, Neurodegeneration, Skin, PSC, Cell biology, Immune system, Commercial, EWA, Therapy, Stem cell, Institute, CPD, Liver, NSCS, NOP, Hormone, Hepatocyte, Medical device

FRANKFURT, Germany, Oct. 27, 2021 /PRNewswire/ European Wellness Academy (EWA), the educational arm of European Wellness Biomedical Group (EWG), has signed an agreement to carry out joint scientific research on the efficacy of peptides, cell therapy, exosomes and cell reprogramming for rejuvenation in premature murine aging models.

Key Points: 
  • FRANKFURT, Germany, Oct. 27, 2021 /PRNewswire/ European Wellness Academy (EWA), the educational arm of European Wellness Biomedical Group (EWG), has signed an agreement to carry out joint scientific research on the efficacy of peptides, cell therapy, exosomes and cell reprogramming for rejuvenation in premature murine aging models.
  • EWA was represented by its Group Chairman, Prof. Dr. Mike Chan, while Heidelberg University was represented by its Commercial Managing Director, Katrin Erk and its Head of Institute of Anatomy and Cell Biology III, Prof. Dr. Thomas Skutella.
  • The cutting-edge therapeutics used for the studies include precursor (progenitor) stem cells (PSC), precursor cells (Frozen Organo Crygenics (FOC)), Mito Organelle (MO), Nano Organo Peptides (NOP) and exosomes.
  • The ongoing specially designed studies are coordinated and designed by Prof. Dr. Thomas Skutella of Heidelberg University, a world-renowned research university and one of Germany's Top 3, Prof. Dr.Mike Chan and scientists of EWG.

European Wellness Collaborates with Heidelberg University Germany to Conduct Efficacy Studies of Peptides and Cell Therapy Research

Retrieved on: 
Wednesday, October 27, 2021
Safety, Lung, EWG, Muscular dystrophy, Peptide, Sleep, Research, Microsoft, Academy, Group, Exosome, Heidelberg University, FOC, Regeneration, Degenerative disease, Eye, Kidney, Medicine, Rejuvenation, B cell, Ageing, Cellular senescence, Neurodegeneration, Skin, PSC, Cell biology, Immune system, Commercial, EWA, Therapy, Stem cell, Institute, CPD, Liver, NSCS, NOP, Hormone, Hepatocyte, Medical device

FRANKFURT, Germany, Oct. 27, 2021 /PRNewswire/ European Wellness Academy (EWA), the educational arm of European Wellness Biomedical Group (EWG), has signed an agreement to carry out joint scientific research on the efficacy of peptides, cell therapy, exosomes and cell reprogramming for rejuvenation in premature murine aging models.

Key Points: 
  • FRANKFURT, Germany, Oct. 27, 2021 /PRNewswire/ European Wellness Academy (EWA), the educational arm of European Wellness Biomedical Group (EWG), has signed an agreement to carry out joint scientific research on the efficacy of peptides, cell therapy, exosomes and cell reprogramming for rejuvenation in premature murine aging models.
  • EWA was represented by its Group Chairman, Prof. Dr. Mike Chan, while Heidelberg University was represented by its Commercial Managing Director, Katrin Erk and its Head of Institute of Anatomy and Cell Biology III, Prof. Dr. Thomas Skutella.
  • The cutting-edge therapeutics used for the studies include precursor (progenitor) stem cells (PSC), precursor cells (Frozen Organo Crygenics (FOC)), Mito Organelle (MO), Nano Organo Peptides (NOP) and exosomes.
  • The ongoing specially designed studies are coordinated and designed by Prof. Dr. Thomas Skutella of Heidelberg University, a world-renowned research university and one of Germany's Top 3, Prof. Dr.Mike Chan and scientists of EWG.

Heidelberg Ion Beam Therapy Center treats first patient using helium ion therapy with RayStation

Retrieved on: 
Monday, October 25, 2021
RaySearch Laboratories, Research, Siemens, Diagnosis, United, Nasdaq Stockholm, Proton, Physics, Cancer, OAS, Carbon, Medical director, TPS, Heidelberg University, Patient, Karolinska Institute, Photon, HDR, University of Texas Health Science Center Department of Radiology, OIS, Ion, HIT, Professor, CEO, Tomotherapy, Helium, TCS, University Hospital Heidelberg, Cyberknife, Electron, Health, Education, Department, Physician, Lawrence Berkeley National Laboratory, Lithium, Medical imaging

STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Heidelberg Ion Beam Therapy Center (HIT) has treated its first patient using helium ion therapy with RayStation* treatment planning system.

Key Points: 
  • STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Heidelberg Ion Beam Therapy Center (HIT) has treated its first patient using helium ion therapy with RayStation* treatment planning system.
  • The procedure went smoothly, and the center will shortly start using their gantry beamline, as well as initiate a larger-scale clinical trial.
  • The treatment planning was performed with RayStation, version 9B, that supports use of helium ions side by side with carbon ions and protons.
  • The center chose RayStation to replace its existing treatment planning systems in 2018 and began proton and carbon ion therapy treatments with RayStation in 2019.

AmeriHealth Caritas Appoints Mark Grippi Market President of its Ohio Medicaid Plan

Retrieved on: 
Wednesday, October 13, 2021
Professional Services, Health, Insurance, Other Health, Managed Care, General Health, Pharmaceutical, Salvatore Grippi, Leadership, Cleveland Clinic, CareSource, CHIP, Growth, Multimedia, Health, Heidelberg University, District, Cleveland, Health insurance, Hospital, AmeriHealth Caritas Ohio, AmeriHealth Caritas, AMERIHEALTH CARITAS OHIO, AMERIHEALTH CARITAS

AmeriHealth Caritas , a national leader in Medicaid managed care and other health care solutions for those most in need, announced it has appointed Mark Grippi as market president of its Ohio Medicaid plan, AmeriHealth Caritas Ohio.

Key Points: 
  • AmeriHealth Caritas , a national leader in Medicaid managed care and other health care solutions for those most in need, announced it has appointed Mark Grippi as market president of its Ohio Medicaid plan, AmeriHealth Caritas Ohio.
  • In April 2021, AmeriHealth Caritas Ohio was chosen to be one of seven health plans serving Ohios Medicaid managed care program.
  • View the full release here: https://www.businesswire.com/news/home/20211013005816/en/
    AmeriHealth Caritas Ohio Market President Mark Grippi.
  • AmeriHealth Caritas Ohio is a managed care organization that is slated to begin serving Ohio Medicaid enrollees in July 2022.

Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management

Retrieved on: 
Tuesday, October 12, 2021
Private Securities Litigation Reform Act, Control, Portfolio strategy, Therapy, Department, Degenerative disease, Engineering, COVID-19, Stem cell, Standard of care, MBA, GLOBE, Cancer, Boehringer Ingelheim, Heidelberg University, U.S. Securities and Exchange Commission, Takeda Oncology, Infection, MBBS, Security (finance), Lymphatic system, Patient, Clinical trial, Pharmaceutical industry

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vors Senior Vice President of Program and Alliance Management.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vors Senior Vice President of Program and Alliance Management.
  • We are excited to welcome Veit to our team during this critical period at Vor as enrollment of our Phase 1/2a clinical trial of VOR33 continues.
  • I joined Vor because I believe in the companys vision: to cure blood cancers through cell and genome engineering, said Dr. Schmelmer.
  • He previously served as Vice President of Portfolio Strategy at Mersana Therapeutics with responsibility for project leadership, alliance management and portfolio strategy.

DGAP-News: Reorganized and strengthened - The Management Board team of centrotherm international AG

Retrieved on: 
Wednesday, September 1, 2021
CTO, Industry, Technology Development Board, University, Karlsruhe Institute of Technology, Supervisory board, AG, Business, Board of directors, Research, Indian Institute of Food Processing Technology, Doctor of Philosophy, KIT, Development, Physics, MBA, Carbon, Heidelberg University, Head, West Coast of Vancouver Island Aquatic Management Board, Solution, GREEN, Research and development, Blaubeuren, University of Konstanz, Management

Reorganized and strengthened - The Management Board team of centrotherm international AG:

Key Points: 
  • Reorganized and strengthened - The Management Board team of centrotherm international AG:
    Blaubeuren, September 01, 2021 - The Supervisory Board of centrotherm international AG has appointed Dr. Helge Haverkamp and Dr. Daniel Rieser as members of the Management Board.
  • Together with CEO Jan von Schuckmann, they form the new Management Board team of the centrotherm Group with effect from today.
  • "With the appointment of the two new Management Board members, we are broadening the top management level, and creating new Management Board responsibilities that are strategically important for the success of the centrotherm Group.
  • I am convinced that, as CTO, he will furthermore fulfill this role with strategic foresight," emphasizes Robert M. Hartung, Chairman of the Supervisory Board of centrotherm international AG.

UPDATE: Cannabis Science Inc., Successfully Launches its $CSI Cannabis Science Coin for its CSi-EDP Utility Project Valuation Tracking, https://cannabissciencecoin.com

Retrieved on: 
Wednesday, August 11, 2021
Crypto, Community, Industry, GHC, Education, Gwinnett Chamber of Commerce, Patent, Drug development, Company, Patient, Commerce, Private Securities Litigation Reform Act, K-12, State, AND, Technology, Hemp, European, WHO, Investment banking, Heidelberg University, Partner, ALL, Phrase, Research, Harvard Medical School, Securities Act of 1933, Failure, University, Success, FDA, Palliative care, Product pipeline, National Security Act 2017 (Canada), Cannabis Science, Growth, FSO, Harvard University, Cryptocurrency, Perfume, Pharmaceutical industry, Cargo, Medicine

Amsterdam, Netherlands, Aug. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Cannabis Science Inc., formerly known as (CBIS) per its previous trading history on the OTC Markets Exchange, is very pleased to announce it has just successfully launched its $CSI Cannabis Science Coin, Utility for CSi-EDP project asset valuation, revenue tracking, and dividend disbursements.  As well, the CSi-EDP will use the $CSI Cannabis Science Coin for several of its transaction-based products and services. Each Cannabis Science CSi-EDP product and or service assigned will become a part of the $CSI Cannabis Science Coin investment banking and economic development ecosystem, thus multiplying the $CSI Cannabis Science Coin value and International reach!

Key Points: 
  • This $CSI Cannabis Science Coin Launch is important for Cannabis Science and we the people; this gives everyone access to the CSi-EDP, you already know the Cannabis Science list.
  • We will bank/assign one Cannabis Science CSI-EDP project at a time through our $CSI Cannabis Science Coin just like Currency, just like an Investment Bank!
  • We will announce each project one by one as we assign it to the $CSI Cannabis Science Coin, in turn the growing in value for each CSI-EDP project added, based on crypto recorded valuations of each project and current $CSI Cannabis Science Coin values at any time.
  • We expect to announce the first project selected for its $CSI Cannabis Science Coin shortly, just a few more updates and growth.